The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Preventing CKD in Developed Countries
Open accessAbstract
Chronic kidney disease (CKD) is an important public health concern in developed countries because of both the number of people affected and the high cost of care when prevention strategies are not effectively implemented. Prevention should start at the governance level with the institution of multisectoral polices supporting sustainable development goals and ensuring safe and healthy environments. Primordial prevention of CKD can be achieved through implementation of measures to ensure healthy fetal (kidney) development. Public health strategies to prevent diabetes, hypertension, and obesity as risk factors for CKD are important. These approaches are cost-effective and reduce the overall noncommunicable disease burden. Strategies to prevent nontraditional CKD risk factors, including nephrotoxin exposure, kidney stones, infections, environmental exposures, and acute kidney injury (AKI), need to be tailored to local needs and epidemiology. Early diagnosis and treatment of CKD risk factors such as diabetes, obesity, and hypertension are key for primary prevention of CKD. CKD tends to occur more frequently and to progress more rapidly among indigenous, minority, and socioeconomically disadvantaged populations. Special attention is required to meet the CKD prevention needs of these populations. Effective secondary prevention of CKD relies on screening of individuals at risk to detect and treat CKD early, using established and emerging strategies. Within high-income countries, barriers to accessing effective CKD therapies must be recognized, and public health strategies must be developed to overcome these obstacles, including training and support at the primary care level to identify individuals at risk of CKD, and appropriately implement clinical practice guidelines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 1×
“Kidney International Reports (2020) 5, 263–277 endpoints.(148,149) From a renal perspective, GLP1RA, liraglutide (LEADER), and semaglutide (SUSTAIN-6) reduced composite renal endpoints, consisting of progression of albuminuria, doubling of serum creatinine level, renal replacement therapy, or renal death.”
BackgroundDapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Ettehad, D., Emdin, C. A., Kiran, A., Anderson, S. G., Callender, T., Emberson, J., Chalmers, J., Rodgers, A., & Rahimi, K. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01225-8 · Cited by 3,755 · cited 1×
“Among these interventions aimed at slowing CKD progression and mitigating CVD outcomes, inhibition of the renin–angiotensin–aldosterone system has yielded the most impact, is cost-effective in high-income settings, and has been adopted as an integral part of CKD management practices worldwide.(6,136) Given that T2D is…”
BackgroundEmpagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655
Stevens, P. E., Levin, A., & for the Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members* (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-158-11-201306040-00007 · Cited by 3,607
Levey, A. S., & Coresh, J. (2012) · The Lancet · doi:10.1016/s0140-6736(11)60178-5 · Cited by 1,841
Primary Care: Is There Enough Time for Prevention?
Yarnall, K. S. H., Pollak, K. I., Østbye, T., Krause, K. M., & Michener, J. L. (2003) · American Journal of Public Health · doi:10.2105/ajph.93.4.635 · Cited by 1,641
Liraglutide and renal outcomes in type 2 diabetes
Mann, J. F. E., Ørsted, D. D., Brown-Frandsen, K., Marso, S. P., Poulter, N. R., Rasmussen, S., Tornøe, K., Zinman, B., & Buse, J. B. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1616011 · Cited by 1,253
Blencowe, H., Krasevec, J., de Onis, M., Black, R. E., An, X., Stevens, G. A., Borghi, E., Hayashi, C., Estevez, D., Cegolon, L., et al. (2019) · The Lancet Global Health · doi:10.1016/s2214-109x(18)30565-5 · Cited by 1,242 · cited 1×
“The incidence of low birth weight in high-income countries has been stable at 7% for >20 years, and is most commonly associated with preterm birth.(29) Both preterm birth and low birth weight occur more frequently among socioeconomically disadvantaged populations and indigenous communities within high-income countries…”
BackgroundA clinically applicable approach to continuous prediction of future acute kidney injury
Tomašev, N., Glorot, X., Rae, J. W., Zielinski, M., Askham, H., Saraiva, A., Mottram, A., Meyer, C., Ravuri, S., Protsyuk, I., et al. (2019) · Nature · doi:10.1038/s41586-019-1390-1 · Cited by 1,086
Is There Time for Management of Patients With Chronic Diseases in Primary Care?
Ostbye, T. (2005) · The Annals of Family Medicine · doi:10.1370/afm.310 · Cited by 698
Obesity, kidney dysfunction and hypertension: mechanistic links
Hall, J. E., do Carmo, J. M., da Silva, A. A., Wang, Z., & Hall, M. E. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0145-4 · Cited by 654
Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Botros, F. T., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31150-x · Cited by 638
Follow-up of blood-pressure lowering and glucose control in type 2 diabetes
Zoungas, S., Chalmers, J., Neal, B., Billot, L., Li, Q., Hirakawa, Y., Arima, H., Monaghan, H., Joshi, R., Colagiuri, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407963 · Cited by 626
Mozaffarian, D., Afshin, A., Benowitz, N. L., Bittner, V., Daniels, S. R., Franch, H. A., Jacobs, D. R., Kraus, W. E., Kris-Etherton, P. M., Krummel, D. A., et al. (2012) · Circulation · doi:10.1161/cir.0b013e318260a20b · Cited by 601 · cited 1×
“Successful public health approaches include introduction of economic incentives to reduce prices of healthy food and beverages and increase taxation on unhealthy products, restriction of food advertising, regulation of food composition (salt, trans fats, sugar), support for education and physical activity programs in…”
BackgroundZhou, B., Danaei, G., Stevens, G. A., Bixby, H., Taddei, C., Carrillo-Larco, R. M., Solomon, B., Riley, L. M., Di Cesare, M., Iurilli, M. L. C., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31145-6 · Cited by 544
Abalos, E., Cuesta, C., Carroli, G., Qureshi, Z., Widmer, M., Vogel, J., Souza, J., & on behalf of the WHO Multicountry Survey on Maternal and Newborn Health Research Network (2014) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/1471-0528.12629 · Cited by 528
Prevalence of chronic kidney disease in US adults with undiagnosed diabetes or prediabetes
Plantinga, L. C., Crews, D. C., Coresh, J., Miller, E. R., Saran, R., Yee, J., Hedgeman, E., Pavkov, M., Eberhardt, M. S., Williams, D. E., et al. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.07891109 · Cited by 408
McGill, R., Anwar, E., Orton, L., Bromley, H., Lloyd-Williams, F., O’Flaherty, M., Taylor-Robinson, D., Guzman-Castillo, M., Gillespie, D., Moreira, P., et al. (2015) · BMC Public Health · doi:10.1186/s12889-015-1781-7 · Cited by 407
Renoprotective effects of sodium-glucose cotransporter-2 inhibitors
Heerspink, H. J. L., Kosiborod, M., Inzucchi, S. E., & Cherney, D. Z. I. (2018) · Kidney International · doi:10.1016/j.kint.2017.12.027 · Cited by 393
Self-citationCrump, C., Sundquist, J., Winkleby, M. A., & Sundquist, K. (2019) · BMJ · doi:10.1136/bmj.l1346 · Cited by 265
Nine-year effects of 3.7 years of intensive glycemic control on cardiovascular outcomes
The ACCORD Study Group (2016) · Diabetes Care · doi:10.2337/dc15-2283 · Cited by 193
Jhee, J. H., Joo, Y. S., Kee, Y. K., Jung, S.-Y., Park, S., Yoon, C.-Y., Han, S. H., Yoo, T.-H., Kang, S.-W., & Park, J. T. (2019) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.09540818 · Cited by 60
Initiative, O. B. O. T. C. F. D. C. A. P. C., Yarnoff, B. O., Hoerger, T. J., Simpson, S. K., Leib, A., Burrows, N. R., Shrestha, S. S., & Pavkov, M. E. (2017) · BMC Nephrology · doi:10.1186/s12882-017-0497-6 · Cited by 55
Harvey, G., Oliver, K., Humphreys, J., Rothwell, K., & Hegarty, J. (2015) · International Journal for Quality in Health Care · doi:10.1093/intqhc/mzu097 · Cited by 21
Preserving Kidney Function Instead of Replacing It
Kliger, A. S., Brosius, F. C., & on behalf of the Diabetic Kidney Disease Task Force of the American Society of Nephrology (2020) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.07820719 · Cited by 20 · cited 1×
“Despite good evidence of their impact, uptake of renin–angiotensin– aldosterone system inhibitors early on was surprisingly slow.(115,137) Medications that inhibit the sodiumglucose cotransporter-2 (SGLT2) and glucagon-like peptide-1 receptor agonists (GLP1RAs) are emerging as important additional therapies for second…”
Background
Metadata
- Authors
- Luyckx, V. A., Cherney, D. Z. I., & Bello, A. K.
- Venue
- Kidney International Reports
- Publisher
- Elsevier BV
- Published
- 2020-03
- Volume
- 5
- Issue
- 3
- Pages
- 263-277
- ISSN
- 2468-0249 (ISSN-L)
- OpenAlex
- W2996172570
- Cited by
- 176
- References
- 31
- FWCI
- 10.77
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.